Goldman Sachs Upgrades CVS Health To Buy

Analysts at Goldman Sachs upgraded

from Neutral to Buy. The price target for CVS Health has been raised from $95 to $113. CVS Health shares have surged 42.21% over the past 52 weeks, while the S&P 500 index has gained 9.63% in the same period. CVS Health's shares fell 0.37% to close at $98.37 yesterday.